GleamWall
中文EN

JSPR Jasper Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1788028 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-73.0%
TTM EPS YoY184.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-153.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets14.2%
Debt / equity—
Current ratio10.59x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.31x
Accruals ratio-106.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
Cost of revenue$41.63M$34.27M
R&D expense$63.10M$55.82M
SG&A expense$20.78M$20.42M
Operating income-$83.88M-$76.24M
Income tax—$2,000
Net income-$75.80M-$71.27M
EBITDA-$82.83M-$74.87M
EPS (basic)-3.95-4.89
EPS (diluted)-3.95-4.89
Weighted avg. shares (diluted)19.17M14.58M
Balance sheet
Cash & equivalents$28.69M$72.05M
Current assets$34.65M$75.81M
PP&E, net$102,000$1.88M
Total assets$35.78M$79.90M
Current liabilities$13.20M$15.24M
Total liabilities$31.63M$18.23M
Shareholders' equity$4.15M$61.67M
Shares outstanding933,24215.02M
Cash flow statement
Operating cash flow-$77.16M-$62.60M
Investing cash flow$5,000-$532,000
Financing cash flow$34.21M$47.88M
Depreciation & amortization$1.06M$1.37M
Stock-based compensation$6.71M$6.62M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.